Five Prime Therapeutics, Inc.

ACTIVE

750 Gateway Blvd, 加利福尼亚州旧金山县, California, United Stateswww.fiveprime.comPublic101–250 employeesEstablished: 2001-01-01

Also known as:

five prime

Part of Amgen, Inc.

Clinical Trials

12 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2001

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

76.9%

Phase 2

11.5%

Early Phase 1

3.9%

Trial Status Distribution

Active, not recruiting

46.1%

Completed

30.8%

No Longer Available

3.9%

Terminated

15.4%

Withdrawn

3.9%

Clinical Trials

Trials sponsored by this organization (26)

A Phase 3 Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase I to be conducted prior to Phase 3

Phase 1

Active, not recruiting

Jan 2021548 participants

A Phase 1a/1b Study of FPT155 in Patients with Advanced Solid Tumors.

Phase 1

Terminated

interventional

Dec 201880 participants

A Phase 2 Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase I to be conducted prior to Phase 2

Phase 1

Active, not recruiting

Nov 2018167 participants

A Phase 3 Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase I to be conducted prior to Phase 3

Phase 1

Active, not recruiting

Nov 2018548 participants

A Phase 3 Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase I to be conducted prior to Phase 3

Phase 1

Active, not recruiting

Nov 2018548 participants

A Phase 3 Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase I to be conducted prior to Phase 3

Phase 1

Active, not recruiting

Oct 2018548 participants

A Phase 2 Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase I to be conducted prior to Phase 2

Phase 1

Active, not recruiting

Oct 2018167 participants

A Phase 3 Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase I to be conducted prior to Phase 3

Phase 1

Active, not recruiting

Oct 2018548 participants

Page 1 of 4

Approvals

No approval data available

News

No news articles found

Back to Organizations